

## Anti-CD19/CD3 Antibody (Blinatumomab)

### Introduction

Blinatumomab is a bispecific T cell engaging antibody (BiTE) developed by Amgen. It consists of two single-chain variable fragments (scFv), one targeting the CD19 antigen and the other targeting the CD3 antigen. Blinatumomab activates the killing effect of T cells on B cells by guiding T cells (CD3 positive) to B cells expressing CD19. The drug is mainly used to treat relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).

### Product parameters

Alternative Names	Blinicyto, Anatumomab
Target Accession	-
Target	CD19/CD3
CAS number	853426-35-4
Molecular Weight	-
Host	CHO
Reactivity	Mouse
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	(scFv-kappa-heavy)-(scFv-heavy-kappa)
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## ■ Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

